Actinium to Present at the 24th Annual Wall Street Analyst Forum Institutional Investor Conference

  Actinium to Present at the 24th Annual Wall Street Analyst Forum
  Institutional Investor Conference

Management to Communicate Its Future Plans and Meet with Conference Attendees

24th Annual Wall Street Analyst Forum Institutional Investor Conference

Business Wire

NEW YORK -- February 26, 2014

Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB) ("Actinium" or "the Company"),
a biopharmaceutical Company developing innovative targeted payload
immunotherapeutics for the treatment of advanced cancers, announces that
Kaushik J. Dave, Ph.D., President and CEO, will present at the 24th Annual
Wall Street Analyst Forum Institutional Investor Conference at the University
Club of New York, located at 1 West 54th Street, New York, NY, on Monday,
March 3, 2014 at 9:05 AM ET.

A live webcast of the presentation will be available at
www.visualwebcaster.com/event.asp?id=98054 and via the “Investor Relations”
page of the Actinium website, www.actiniumpharmaceuticals.com. A replay of the
webcast will be archived on Actinium’s website for 90 days following the
presentation.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. (ATNM.OB) is a New York-based biopharmaceutical
company developing innovative targeted payload immunotherapeutics for the
treatment of advanced cancers. Actinium's targeted radiotherapy is based on
its proprietary delivery platform for the therapeutic utilization of
alpha-emitting actinium-225 and bismuth-213 and certain beta emitting
radiopharmaceuticals in conjunction with monoclonal antibodies. The Company’s
lead radiopharmaceutical Iomab™-B will be used in preparing patients for
hematopoietic stem cell transplant, commonly referred to as bone marrow
transplant. The Company is conducting a single, pivotal, multicenter Phase 3
clinical study of Iomab™-B in refractory and relapsed Acute Myeloid Leukemia
(AML) patients over the age of 55 with a primary endpoint of durable complete
remission. The company’s second program, Actimab-A, is continuing its clinical
development in a Phase 1/2 trial for newly diagnosed AML patients over the age
of 60 in a single-arm multicenter trial. For more information, please visit
www.actiniumpharmaceuticals.com.

For more information:

Visit our web site www.actiniumpharmaceuticals.com

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.

This news release contains “forward-looking statements” as defined in the
Private Securities Litigation Reform Act of 1995. These statements are based
on management's current expectations and involve risks and uncertainties,
which may cause actual results to differ materially from those set forth in
the statements. The forward-looking statements may include statements
regarding product development, product potential, or financial performance. No
forward-looking statement can be guaranteed and actual results may differ
materially from those projected. Actinium Pharmaceuticals undertakes no
obligation to publicly update any forward-looking statement, whether as a
result of new information, future events, or otherwise.

Contact:

Actinium Pharmaceuticals, Inc.
Investor/Media Relations:
Corey Sohmer, 646-459-4201
csohmer@actiniumpharmaceuticals.com
 
Press spacebar to pause and continue. Press esc to stop.